Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (169)	8/27/2002 2:15:46 PM
From: tuck	Read Replies (1) \| Respond to of 447

Vector1, I haven't followed OSIP as closely as some until fairly recently, and Pfizer hardly at all. However, RC Mac recently posted the following on the Valuation thread: "In order for PFE to obtain FTC antitrust clearance for its takeover of WLA two years ago, PFE had the choice either to give up Tarceva (then OSI-774, which OSIP had licensed to WLA) or to give up another EGFR inhibitor developed by PFE, which [from memory only] I believe has since failed)." Message 17905900 Is CI-1033 the compound referred to here? Don't know, but it clearly hasn't failed yet, and PFE still has it. Also don't know if Pfizer was forced to choose between Tarceva and a specific compound or if Pfizer got to choose which of its EGFr inhibitors under development to terminate. In any case, it would appear Pfizer sacrificed potential to be among the first to market (via Tarceva) for the potential to come in later with a more effective drug. That was my point. Cheers, Tuck